Organisation: AbbVie Inc

FTC supports Bystolic pay-for-delay case

The Federal Trade Commission has backed private plaintiffs seeking the reinstatement of their claims that an AbbVie subsidiary illegally delayed generic competition for its hypertension drug.

22 June 2023

Hausfeld leads Dutch excessive pricing claim against AbbVie

An Amsterdam-based non-profit is seeking a court declaration that AbbVie abused its dominance by overcharging the national healthcare system over €1 billion for its rheumatoid arthritis treatment drug.

22 February 2023

Netherlands: Price and Supply Security Remain Regulator’s Top Priorities

Featured in The Guide to Life Sciences - First Edition

Providing consumers with access to medicines at a reasonable price is the key driver of regulatory and legislative change in the life sciences sector in the Netherlands.

21 October 2022

Unlock unlimited access to all Global Competition Review content